Valion Bio, Inc. (VBIO): Nasdaq/NYSE listing notice — Tivic Health receives Nasdaq delisting notice; hearing requested, reverse split proposed

Valion Bio, Inc.

Nasdaq notified Tivic on Dec 27, 2024 it failed to regain $1.00 bid price compliance and is ineligible for a second 180-day period due to equity deficiency.
Company requested a hearing on Jan 3, 2025, which automatically stays any suspension or delisting pending the hearing and Panel decision.
Special stockholder meeting set for Jan 31, 2025 to vote on reverse stock split (ratio 1:2 to 1:30) to regain bid price compliance.
No assurance that the company will regain compliance or that the Nasdaq Panel will grant continued listing.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Valion Bio, Inc. received a nasdaq delisting notice notice regarding stockholders equity.

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity

Exact text from the filing

December 27, 2024, the Company received an additional letter from Nasdaq, notifying the Company that it has not regained compliance with the Rule and is not eligible for a second 180-day remediation period. Specifically

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Valion Bio, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

December 27, 2024, the Company received an additional letter from Nasdaq, notifying the Company that it has not regained compliance with the Rule and is not eligible for a second 180-day remediation period. Specifically

View on SEC.gov

Browse all listing & compliance notices →

Valion Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-001140

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.